Literature DB >> 20233975

Generation of iPSCs from cultured human malignant cells.

Jan E Carette1, Jan Pruszak, Malini Varadarajan, Vincent A Blomen, Sumita Gokhale, Fernando D Camargo, Marius Wernig, Rudolf Jaenisch, Thijn R Brummelkamp.   

Abstract

Induced pluripotent stem cells (iPSCs) can be generated from various differentiated cell types by the expression of a set of defined transcription factors. So far, iPSCs have been generated from primary cells, but it is unclear whether human cancer cell lines can be reprogrammed. Here we describe the generation and characterization of iPSCs derived from human chronic myeloid leukemia cells. We show that, despite the presence of oncogenic mutations, these cells acquired pluripotency by the expression of 4 transcription factors and underwent differentiation into cell types derived of all 3 germ layers during teratoma formation. Interestingly, although the parental cell line was strictly dependent on continuous signaling of the BCR-ABL oncogene, also termed oncogene addiction, reprogrammed cells lost this dependency and became resistant to the BCR-ABL inhibitor imatinib. This finding indicates that the therapeutic agent imatinib targets cells in a specific epigenetic differentiated cell state, and this may contribute to its inability to fully eradicate disease in chronic myeloid leukemia patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233975      PMCID: PMC2875096          DOI: 10.1182/blood-2009-07-231845

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Oct4-induced pluripotency in adult neural stem cells.

Authors:  Jeong Beom Kim; Vittorio Sebastiano; Guangming Wu; Marcos J Araúzo-Bravo; Philipp Sasse; Luca Gentile; Kinarm Ko; David Ruau; Mathias Ehrich; Dirk van den Boom; Johann Meyer; Karin Hübner; Christof Bernemann; Claudia Ortmeier; Martin Zenke; Bernd K Fleischmann; Holm Zaehres; Hans R Schöler
Journal:  Cell       Date:  2009-02-06       Impact factor: 41.582

2.  Broader implications of defining standards for the pluripotency of iPSCs.

Authors:  George Q Daley; M William Lensch; Rudolf Jaenisch; Alex Meissner; Kathrin Plath; Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2009-03-06       Impact factor: 24.633

3.  c-Myc is dispensable for direct reprogramming of mouse fibroblasts.

Authors:  Marius Wernig; Alexander Meissner; John P Cassady; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2007-12-13       Impact factor: 24.633

4.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

5.  Generation of induced pluripotent stem cells from human blood.

Authors:  Yuin-Han Loh; Suneet Agarwal; In-Hyun Park; Achia Urbach; Hongguang Huo; Garrett C Heffner; Kitai Kim; Justine D Miller; Kitwa Ng; George Q Daley
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

6.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

7.  Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency.

Authors:  Jacob Hanna; Styliani Markoulaki; Patrick Schorderet; Bryce W Carey; Caroline Beard; Marius Wernig; Menno P Creyghton; Eveline J Steine; John P Cassady; Ruth Foreman; Christopher J Lengner; Jessica A Dausman; Rudolf Jaenisch
Journal:  Cell       Date:  2008-04-18       Impact factor: 41.582

8.  Principles of cancer therapy: oncogene and non-oncogene addiction.

Authors:  Ji Luo; Nicole L Solimini; Stephen J Elledge
Journal:  Cell       Date:  2009-03-06       Impact factor: 41.582

Review 9.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

10.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.

Authors:  Masato Nakagawa; Michiyo Koyanagi; Koji Tanabe; Kazutoshi Takahashi; Tomoko Ichisaka; Takashi Aoi; Keisuke Okita; Yuji Mochiduki; Nanako Takizawa; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2007-11-30       Impact factor: 54.908

View more
  116 in total

1.  Induced Pluripotent Stem Cells-A New Foundation in Medicine.

Authors:  George T-J Huang
Journal:  J Exp Clin Med       Date:  2010-10-22

Review 2.  Functional genomics to uncover drug mechanism of action.

Authors:  Sebastian M B Nijman
Journal:  Nat Chem Biol       Date:  2015-11-17       Impact factor: 15.040

3.  Nuclear reprogramming and the cancer genome.

Authors: 
Journal:  Nat Genet       Date:  2013-09       Impact factor: 38.330

4.  HIF induces human embryonic stem cell markers in cancer cells.

Authors:  Julie Mathieu; Zhan Zhang; Wenyu Zhou; Amy J Wang; John M Heddleston; Claudia M A Pinna; Alexis Hubaud; Bradford Stadler; Michael Choi; Merav Bar; Muneesh Tewari; Alvin Liu; Robert Vessella; Robert Rostomily; Donald Born; Marshall Horwitz; Carol Ware; C Anthony Blau; Michele A Cleary; Jeremy N Rich; Hannele Ruohola-Baker
Journal:  Cancer Res       Date:  2011-06-28       Impact factor: 12.701

Review 5.  Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9.

Authors:  Hua Shen; Cliona M McHale; Martyn T Smith; Luoping Zhang
Journal:  Mutat Res Rev Mutat Res       Date:  2015-01-25       Impact factor: 5.657

6.  A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors.

Authors:  Hongzhi Zhao; Timothy J Davies; Jiaolin Ning; Yanxu Chang; Patty Sachamitr; Susanne Sattler; Paul J Fairchild; Fang-Ping Huang
Journal:  Cell Reprogram       Date:  2014-12-30       Impact factor: 1.987

7.  Patient-derived induced pluripotent stem cells in cancer research and precision oncology.

Authors:  Eirini P Papapetrou
Journal:  Nat Med       Date:  2016-12-06       Impact factor: 53.440

8.  Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles.

Authors:  Kaifeng Shao; Carmen Koch; Manoj K Gupta; Qiong Lin; Michael Lenz; Stephanie Laufs; Bernd Denecke; Manfred Schmidt; Matthias Linke; Hans C Hennies; Jürgen Hescheler; Martin Zenke; Ulrich Zechner; Tomo Šarić; Wolfgang Wagner
Journal:  Mol Ther       Date:  2012-10-02       Impact factor: 11.454

Review 9.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

10.  microRNA-based cancer cell reprogramming technology.

Authors:  Shimpei Nishikawa; Hideshi Ishii; Naotsugu Haraguchi; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Miyuki Ozaki; Dyah Laksmi Dewi; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.